Clinical trial with Corynebacterium parvum. 1977

R Medenica, and J P Girard, and P Maurice

Corynebacterium parvum was administered to sixteen patients with malignant tumors submitted to repeated chemotherapy courses. A total of 428 injections of C. parvum at a dose of 3.5 mg/m2 in weekly, biweekly and monthly administration was given between the chemotherapy courses. Injection of C. parvum was followed by fever and local pain in 15/16 patients. Three patients presented a local ulceration during the initial period of weekly injections. Splenomegaly was observed after the second month of treatment, peripheral and bone-marrow monocytic infiltration after the second month. The decreased lymphocyte stimulation by PHA observed during the first two months was followed by an increased response. Cutaneous reactions to three antigens increased progressively in most patients and negative pre-treatment tests became positive after treatment.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011425 Propionibacterium acnes A bacteria isolated from normal skin, intestinal contents, wounds, blood, pus, and soft tissue abscesses. It is a common contaminant of clinical specimens, presumably from the skin of patients or attendants. Corynebacterium acnes,Corynebacterium parvum
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Medenica, and J P Girard, and P Maurice
January 1977, Developments in biological standardization,
R Medenica, and J P Girard, and P Maurice
January 1976, Clinical bulletin,
R Medenica, and J P Girard, and P Maurice
July 1976, Lancet (London, England),
R Medenica, and J P Girard, and P Maurice
August 1987, British journal of hospital medicine,
R Medenica, and J P Girard, and P Maurice
January 1995, Chest,
R Medenica, and J P Girard, and P Maurice
March 1978, Annals of allergy,
R Medenica, and J P Girard, and P Maurice
November 1978, Lancet (London, England),
R Medenica, and J P Girard, and P Maurice
October 1976, Lancet (London, England),
R Medenica, and J P Girard, and P Maurice
January 1976, Annals of the New York Academy of Sciences,
Copied contents to your clipboard!